Contributions
Abstract: P962
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Immunology
Introduction: Differences in leukocyte populations in the cerebrospinal fluid (CSF) between Multiple Sclerosis (MS) and other neurological pathologies have been reported. However is not fully elucidated which leucocytes subsets and cytokines producing cells are the major players on MS compared to other inflammatory (OIND) and non inflammatory (NIND) diseases of the central nervous system (CNS).
Objective: To explore immune intrathecal phenotypes that may help to identify MS patients from other diseases of the CNS and get insights on the physiopathology of the disease.
Patients and methods: 115 consecutive MS patients, 31 with other inflammatory diseases (IND) and 30 with non-inflammatory disease (NIND) were included in this study. We studied by flow cytometry the percentages and total cells counts of different lymphocyte and monocyte subsets present in CSF and the intracellular cytokine production (INF-γ, TNF-α, IL-22, IL-17) on CSF T cells.
Results: MS patients showed higher percentages and total cell counts of regulatory T cells (p< 0.0001), CD62L+CD4+ (p=0.0011) and B cells (p< 0.0001) than OIND and NIND patients. In addition, OIND group showed higher percentages and total cell counts of CD4 T cells producing IL-22 and IL-17 (p< 0.0001) than the other groups while MS patients had higher cell counts of CD4 and CD8 T cells producing TNF-α and INF-γ (p< 0.0001;p< 0.0001). Alternatively, NIND patients showed higher percentages of monocytes (p=0.0002), this increase was due to classical (p=0.0024) and alternative (p< 0.0001) subsets.
Conclusions: We have observed different leukocyte patterns in CSF of patients with MS and other inflammatory and non inflammatory neurological diseases. This contributes to elucidate the immunological mechanisms playing a role in MS.
Disclosure: LM Villar received speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis; L Costa Frossard received speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis. JC Alvarez-Cermeño received speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis; S Sainz de la Maza received honoraria from Genzyme and Biogen; C Picón, Y Aladro, E Rodriguez-Martin, S Medina, have nothing to disclose.
This project is supported by FIS PI12-00239 and SAF 2012-34670 projects from the Spanish Ministry of Economy and Competitivity.
Abstract: P962
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Immunology
Introduction: Differences in leukocyte populations in the cerebrospinal fluid (CSF) between Multiple Sclerosis (MS) and other neurological pathologies have been reported. However is not fully elucidated which leucocytes subsets and cytokines producing cells are the major players on MS compared to other inflammatory (OIND) and non inflammatory (NIND) diseases of the central nervous system (CNS).
Objective: To explore immune intrathecal phenotypes that may help to identify MS patients from other diseases of the CNS and get insights on the physiopathology of the disease.
Patients and methods: 115 consecutive MS patients, 31 with other inflammatory diseases (IND) and 30 with non-inflammatory disease (NIND) were included in this study. We studied by flow cytometry the percentages and total cells counts of different lymphocyte and monocyte subsets present in CSF and the intracellular cytokine production (INF-γ, TNF-α, IL-22, IL-17) on CSF T cells.
Results: MS patients showed higher percentages and total cell counts of regulatory T cells (p< 0.0001), CD62L+CD4+ (p=0.0011) and B cells (p< 0.0001) than OIND and NIND patients. In addition, OIND group showed higher percentages and total cell counts of CD4 T cells producing IL-22 and IL-17 (p< 0.0001) than the other groups while MS patients had higher cell counts of CD4 and CD8 T cells producing TNF-α and INF-γ (p< 0.0001;p< 0.0001). Alternatively, NIND patients showed higher percentages of monocytes (p=0.0002), this increase was due to classical (p=0.0024) and alternative (p< 0.0001) subsets.
Conclusions: We have observed different leukocyte patterns in CSF of patients with MS and other inflammatory and non inflammatory neurological diseases. This contributes to elucidate the immunological mechanisms playing a role in MS.
Disclosure: LM Villar received speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis; L Costa Frossard received speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis. JC Alvarez-Cermeño received speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis; S Sainz de la Maza received honoraria from Genzyme and Biogen; C Picón, Y Aladro, E Rodriguez-Martin, S Medina, have nothing to disclose.
This project is supported by FIS PI12-00239 and SAF 2012-34670 projects from the Spanish Ministry of Economy and Competitivity.